New study shows mainframes still popular despite the rise of cloud—though times are changing…fast

A whitepaper from the DTCC and Celent finds that 67% of buy- and sell-side firms hope to be “cloud first” by 2024, but mainframes still part of the equation.

Arguably the most challenging decisions facing a head of technology or data is determining which workflows, data, and applications should be migrated to the cloud, and what that timeframe should look like. Yet while the cloud might seem inevitable, a new report that surveyed financial institutions across the buy and sell side shows that most firms still rely on legacy technology for their datacenter needs.

The report, which was conducted by the Depository Trust & Clearing Corporation (DTCC) and

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

If you already have an account, please sign in here.

Interop tech buys time for buy-side fixed-income traders

A few buy-side traders and portfolio managers spearheading a drive for greater interoperability are reaping the rewards of increased workplace efficiency. Is interoperability the fixed-income panacea the buy side has been looking for?

GenAI and HFT: A competitive edge?

Timing is critical in the capital markets. IBM researchers say genAI’s predictive abilities in combination with AI/ML models can translate into profitable HFT opportunities.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here